Emir Celik1, Hande Mefkure Ozkaya2, Burc Cagri Poyraz3, Tarik Saglam3, Pinar Kadioglu4,5. 1. Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey. 2. Department of Endocrinology and Metabolism, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey. 3. Department of Psychiatry, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey. 4. Department of Endocrinology and Metabolism, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey. kadioglup@yahoo.com. 5. Pituitary Center, Istanbul University, Istanbul, Turkey. kadioglup@yahoo.com.
Abstract
OBJECTIVE: To assess prospectively the prevalence of impulse control disorders (ICD), psychiatric symptoms, and their clinical correlates in patients with prolactinoma receiving dopamine agonists (DA) in comparison to those with non-functioning pituitary adenomas (NFA) and healthy controls (HC). METHODS: A total of 25 patients with prolactinoma, 31 with NFA, and 32 HCs were included in the study. All patients and controls were screened for the presence of ICDs and other psychiatric disorders using revised version of Minnesota Impulsive Disorders Interview (MIDI-R), Barratt Impulsiveness Scale (BIS-11), Symptom Check List (SCL-90-R) questionnaire and Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). RESULTS: We detected two new cases (8%) of ICD associated with DAs. Both cases presented with hypersexuality, which reversed totally or decreased upon discontinuation of the drug. The re-challenge of the DA in a smaller dose has led to either no symptoms or weaker symptoms than before. There was an increase in the number of patients who screened positive on obsession, interpersonal sensitivity, paranoid ideation, and additional items subscales of SCL-90-R in comparison to HCs at the end of the study period (p < 0.05 for all). Likewise, cumulative DA dose was positively correlated to obsession, interpersonal sensitivity, paranoid ideation, hostility, phobic anxiety subscales, and GSI scores of SCL-90-R (p < 0.05 for all). CONCLUSIONS: DAs are associated with a small but substantial short-term risk of ICD development and a broad range of psychiatric symptoms in patients with prolactinoma receiving DAs.
OBJECTIVE: To assess prospectively the prevalence of impulse control disorders (ICD), psychiatric symptoms, and their clinical correlates in patients with prolactinoma receiving dopamine agonists (DA) in comparison to those with non-functioning pituitary adenomas (NFA) and healthy controls (HC). METHODS: A total of 25 patients with prolactinoma, 31 with NFA, and 32 HCs were included in the study. All patients and controls were screened for the presence of ICDs and other psychiatric disorders using revised version of Minnesota Impulsive Disorders Interview (MIDI-R), Barratt Impulsiveness Scale (BIS-11), Symptom Check List (SCL-90-R) questionnaire and Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). RESULTS: We detected two new cases (8%) of ICD associated with DAs. Both cases presented with hypersexuality, which reversed totally or decreased upon discontinuation of the drug. The re-challenge of the DA in a smaller dose has led to either no symptoms or weaker symptoms than before. There was an increase in the number of patients who screened positive on obsession, interpersonal sensitivity, paranoid ideation, and additional items subscales of SCL-90-R in comparison to HCs at the end of the study period (p < 0.05 for all). Likewise, cumulative DA dose was positively correlated to obsession, interpersonal sensitivity, paranoid ideation, hostility, phobic anxiety subscales, and GSI scores of SCL-90-R (p < 0.05 for all). CONCLUSIONS:DAs are associated with a small but substantial short-term risk of ICD development and a broad range of psychiatric symptoms in patients with prolactinoma receiving DAs.
Authors: Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang Journal: Arch Neurol Date: 2010-05
Authors: Maya Barake; A Eden Evins; Luke Stoeckel; Gladys N Pachas; Lisa B Nachtigall; Karen K Miller; Beverly M K Biller; Nicholas A Tritos; Anne Klibanski Journal: Pituitary Date: 2014-04 Impact factor: 4.107
Authors: Irina Bancos; Michael R Nannenga; J Michael Bostwick; Michael H Silber; Dana Erickson; Todd B Nippoldt Journal: Clin Endocrinol (Oxf) Date: 2013-12-16 Impact factor: 3.478
Authors: W A Bashari; M van der Meulen; J MacFarlane; D Gillett; R Senanayake; L Serban; A S Powlson; A M Brooke; D J Scoffings; J Jones; D G O'Donovan; J Tysome; T Santarius; N Donnelly; I Boros; F Aigbirhio; S Jefferies; H K Cheow; I A Mendichovszky; A G Kolias; R Mannion; O Koulouri; M Gurnell Journal: Pituitary Date: 2022-05-24 Impact factor: 3.599
Authors: M Zibetti; S Grottoli; G Beccuti; F Guaraldi; G Natta; V Cambria; N Prencipe; A Cicolin; E Montanaro; L Lopiano; E Ghigo Journal: J Endocrinol Invest Date: 2020-12-12 Impact factor: 4.256
Authors: José Miguel Hinojosa-Amaya; Nathaniel Johnson; Christina González-Torres; Elena V Varlamov; Christine G Yedinak; Shirley McCartney; Maria Fleseriu Journal: Front Endocrinol (Lausanne) Date: 2020-10-27 Impact factor: 5.555